Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis
Songqiao Liu,Chen Yao,Jianfeng Xie,Hong Liu,Hongliang Wang,Zhaofen Lin,Bingyu Qin,Difen Wang,Weihua Lu,Xiaochun Ma,Yan Liu,Ling Liu,Chi Zhang,Lei Xu,Ruiqiang Zheng,Feihu Zhou,Zhongmin Liu,Guoqiang Zhang,Lixin Zhou,Jian Liu,Aihua Fei,Guoxiu Zhang,Yimin Zhu,Kejian Qian,Ruilan Wang,Yafeng Liang,Meili Duan,Dawei Wu,Rongqing Sun,Ying Wang,Xijing Zhang,Quan Cao,Mingshi Yang,Minggen Jin,Yan Song,Ling Huang,Fachun Zhou,Dechang Chen,Qun Liang,Chuanyun Qian,Zhongzhi Tang,Zhong Zhang,Qiming Feng,Zhiyong Peng,Renhua Sun,Zhenju Song,Yunbo Sun,Yanfen Chai,Lihua Zhou,Chen Cheng,Li Li,Xiaoyan Yan,Junhua Zhang,Yingzi Huang,Fengmei Guo,Chuan Li,Yi Yang,Hongcai Shang,Haibo Qiu,Wenxue Liu,Meixia Shang,Jibin Han,Ming Li,Linhao Ma,Yunpeng Li,Yuanyi Liu,Tao Yu,Xin Li,Xing Lu,Qihong Chen,Yimin Yang,Yan Li,Weiguang Guo,Zhimin Dou,Chengjin Gao,Dahuan Li,Xiaotong Han,Qiang Shao,Yun Xie,Xiaoli Li,Jin Lin,Zhi Li,Min Gao,Yunxi Song,Binxiao Su,Yun Liu,Yue Peng,Qingsong Cui,Huichao Yu,Baocai Fu,Shihui Lin,Yanxia Huang,Xuedan Cao,Xiao Wang,Qing Fang,Ruolan Huang,Kaichao Yang,Ying Feng,Fangxiao Gong,Jun Yin,Shixia Cai,Shixin Li,Jingchao Wang,Wenke Zheng,
DOI: https://doi.org/10.1001/jamainternmed.2023.0780
2023-05-01
JAMA Internal Medicine
Abstract:Importance Previous research has suggested that Xuebijing injection (XBJ), an herbal-based intravenous preparation, may reduce mortality among patients with sepsis. Objective To determine the effect of XBJ vs placebo on 28-day mortality among patients with sepsis. Design, Setting, and Participants The Efficacy of Xuebijing Injection in Patients With Sepsis (EXIT-SEP) trial was a multicenter, randomized double-blind, placebo-controlled trial conducted in intensive care units at 45 sites and included 1817 randomized patients with sepsis (sepsis 3.0) present for less than 48 hours. Patients aged 18 to 75 years with a Sequential Organ Failure Assessment score of 2 to 13 were enrolled. The study was conducted from October 2017 to June 2019. The final date of follow-up was July 26, 2019. Data analysis was performed from January 2020 to August 2022. Interventions The patients were randomized to receive either intravenous infusion of XBJ (100 mL, n = 911) or volume-matched saline placebo (n = 906) every 12 hours for 5 days. Main Outcomes and Measures The primary outcome was 28-day mortality. Results Among the 1817 patients who were randomized (mean [SD] age, 56.5 [13.5] years; 1199 [66.0%] men), 1760 (96.9%) completed the trial. In these patients, the 28-day mortality rate was significantly different between the placebo group and the XBJ group (230 of 882 patients [26.1%] vs 165 of 878 patients [18.8%], respectively; P < .001). The absolute risk difference was 7.3 (95% CI, 3.4-11.2) percentage points. The incidence of adverse events was 222 of 878 patients (25.3%) in the placebo group and 200 of 872 patients (22.9%) in the XBJ group. Conclusions and Relevance In this randomized clinical trial among patients with sepsis, the administration of XBJ reduced 28-day mortality compared with placebo. Trial Registration ClinicalTrials.gov Identifier: NCT03238742
medicine, general & internal